Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clone Wars: Quantitatively Understanding Cancer Drug Resistance

Clone Wars: Quantitatively Understanding Cancer Drug Resistance A key aim of early clinical development for new cancer treatments is to detect the potential for efficacy early and to identify a safe therapeutic dose to take forward to phase II. Because of this need, researchers have sought to build mathematical models linking initial radiologic tumor response, often assessed after 6 to 8 weeks of treatment, with overall survival. However, there has been mixed success of this approach in the literature. We argue that evolutionary selection pressure should be considered to interpret these early efficacy signals and so optimize cancer therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO Clinical Cancer Informatics Wolters Kluwer Health

Clone Wars: Quantitatively Understanding Cancer Drug Resistance

Loading next page...
 
/lp/wolters-kluwer-health/clone-wars-quantitatively-understanding-cancer-drug-resistance-m1oiZp6c94
Publisher
Wolters Kluwer Health
Copyright
(C) 2020 American Society of Clinical Oncology
ISSN
2473-4276
DOI
10.1200/CCI.20.00089
Publisher site
See Article on Publisher Site

Abstract

A key aim of early clinical development for new cancer treatments is to detect the potential for efficacy early and to identify a safe therapeutic dose to take forward to phase II. Because of this need, researchers have sought to build mathematical models linking initial radiologic tumor response, often assessed after 6 to 8 weeks of treatment, with overall survival. However, there has been mixed success of this approach in the literature. We argue that evolutionary selection pressure should be considered to interpret these early efficacy signals and so optimize cancer therapy.

Journal

JCO Clinical Cancer InformaticsWolters Kluwer Health

Published: Oct 28, 2020

References